FDA Approves Macitentan, Tadalafil Combination Tablet for Pulmonary Arterial Hypertension

The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study.

Related Keywords

Kelly Chin ,Ut Southwestern Medical Center ,Johnson ,Pulmonary Hypertension Program ,Internal Medicine ,Medical Center ,Boxed Warning ,Macitentan Containing Products Risk Evaluation ,Mitigation Strategy ,Global Therapeutic Area Head ,